Search results for "very"

showing 10 items of 6927 documents

Antimicrobial and Antibiofilm Activity of a Recombinant Fragment of β-Thymosin of Sea Urchin Paracentrotus lividus

2018

With the aim to obtain new antimicrobials against important pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, we focused on antimicrobial peptides (AMPs) from Echinoderms. An example of such peptides is Paracentrin 1 (SP1), a chemically synthesised peptide fragment of a sea urchin thymosin. In the present paper, we report on the biological activity of a Paracentrin 1 derivative obtained by recombination. The recombinant paracentrin RP1, in comparison to the synthetic SP1, is 22 amino acids longer and it was considerably more active against the planktonic forms of S. aureus ATCC 25923 and P. aeruginosa ATCC 15442 at concentrations of 50 &micro

0301 basic medicineSettore BIO/05 - ZoologiaPharmaceutical Science<i>Staphylococcus aureus</i>Peptide<i>Paracentrotus lividus</i>Settore BIO/19 - Microbiologia Generalemedicine.disease_causebiofilmDrug DiscoveryPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5chemistry.chemical_classificationbiologyMicrobial Sensitivity TestChemistrymolecular dynamicBiological activityRecombinant ProteinAntimicrobialRecombinant ProteinsAnti-Bacterial AgentsBiochemistrySettore CHIM/03 - Chimica Generale E InorganicaStaphylococcus aureusPeptidePseudomonas aeruginosaStaphylococcus aureuParacentrotusAntibacterial activityAMP (antimicrobial peptides)Staphylococcus aureusSea UrchinAntimicrobial peptidesMicrobial Sensitivity TestsParacentrotus lividusArticle03 medical and health sciencesAnti-Bacterial AgentmedicineAnimalsAMP (antimicrobial peptides); Paracentrotus lividus; Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; molecular dynamics; thymosinAnimalBiofilmthymosinbiology.organism_classificationmolecular dynamics<i>Pseudomonas aeruginosa</i>030104 developmental biologylcsh:Biology (General)Paracentrotus lividusBiofilmsSea UrchinsParacentrotuPeptidesParacentrotus lividuMarine Drugs
researchProduct

Discovering discriminative graph patterns from gene expression data

2016

We consider the problem of mining gene expression data in order to single out interesting features characterizing healthy/unhealthy samples of an input dataset. We present an approach based on a network model of the input gene expression data, where there is a labelled graph for each sample. To the best of our knowledge, this is the first attempt to build a different graph for each sample and, then, to have a database of graphs for representing a sample set. Our main goal is that of singling out interesting differences between healthy and unhealthy samples, through the extraction of "discriminative patterns" among graphs belonging to the two different sample sets. Differently from the other…

0301 basic medicineSettore INF/01 - Informaticabusiness.industryComputer science0206 medical engineeringpattern discovery subgraph extraction biological networksPattern recognition02 engineering and technologyGraph03 medical and health sciencesComputingMethodologies_PATTERNRECOGNITION030104 developmental biologyDiscriminative modelGraph patternsArtificial intelligencebusiness020602 bioinformaticsBiological networkNetwork modelProceedings of the 31st Annual ACM Symposium on Applied Computing
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.

2015

Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis, are among the most common chronic diseases and their prevalence is increasing. Each of these diseases is characterized by the secretion of cytokines and pro-inflammatory molecules which are thought to play a critical role in their pathogenesis. Moreover, immune cells, particularly neutrophils, macrophages and dendritic cells as well structural cells such as epithelial and airway smooth muscle cells are also involved in the pathogenic cycle of these diseases. There is a pressing need for the development of new therapies for these pulmonary diseases, particularly as no existing treatment has bee…

0301 basic medicineSmall interfering RNARespiratory diseasessiRNA deliveryHMGB1 (high-mobility group box 1)medicine.medical_treatmentGenetic enhancementOligonucleotidesPharmaceutical Science02 engineering and technologyBiologySmall InterferingPathogenesis03 medical and health sciencesIdiopathic pulmonary fibrosisImmune systemRNA interferenceNucleic AcidsmedicineAnimalsHumansAntisenseHMGB1 ProteinRNA Small InterferingCatalyticLungNABDs deliveryDNADNA CatalyticGenetic TherapyOligonucleotides Antisense021001 nanoscience & nanotechnologymedicine.diseaseRespiration Disorders030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyChronic DiseaseRNAInflammation Mediators0210 nano-technologyHMGB1 (high-mobility group box 1); Inflammation mediators; NABDs delivery; Respiratory diseases; siRNA delivery; Animals; Chronic Disease; DNA Catalytic; HMGB1 Protein; Humans; Inflammation Mediators; Nucleic Acids; Oligonucleotides Antisense; RNA Small Interfering; Respiration Disorders; Genetic TherapyCurrent drug delivery
researchProduct

P/CAF-mediated spermidine acetylation regulates histone acetyltransferase activity

2016

Histones and polyamines are important determinants of the chromatin structure. Histones form the core of nucleosome particles and their modification by acetylation of N-terminal tails is involved in chromatin structural changes and transcriptional regulation. Polyamines, including spermidine, are also targets of both cytoplasmic and nuclear acetylation, which in turn alters their affinity for DNA and nucleosomes. Previous studies report the interplay between polyamines metabolism and levels of histone acetylation, but the molecular basis of this effect is still unclear. In this work, we have analyzed the in vitro effect of spermidine on histone H3 acetylation catalyzed by P/CAF, a highly co…

0301 basic medicineSpermidine acetylationSpermidineSAP30BiologyHistones03 medical and health sciences0302 clinical medicineHistone H1Drug DiscoveryHistone H2AAnimalsHistone acetyltransferase activityp300-CBP Transcription FactorsHistone octamerHistone H3 acetylationHistone AcetyltransferasesPolytene ChromosomesPharmacologyAcetylationGeneral MedicineHistone acetyltransferaseEnzyme ActivationKineticsDrosophila melanogaster030104 developmental biologyBiochemistry030220 oncology & carcinogenesisbiology.proteinJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

Targeting Bacterial Sortase A with Covalent Inhibitors: 27 New Starting Points for Structure-Based Hit-to-Lead Optimization.

2019

Because of its essential role as a bacterial virulence factor, enzyme sortase A (SrtA) has become an attractive target for the development of new antivirulence drugs against Gram-positive infections. Here we describe 27 compounds identified as covalent inhibitors of

0301 basic medicineStaphylococcus aureusMagnetic Resonance SpectroscopyAntivirulenceVirulence Factors030106 microbiologySmall Molecule Libraries03 medical and health sciencesMiceBacterial ProteinsCatalytic DomainDrug DiscoveryAnimalschemistry.chemical_classificationBinding SitesChemistryHit to leadFibroblastsAminoacyltransferasesAnti-Bacterial AgentsMolecular Docking SimulationCysteine Endopeptidases030104 developmental biologyInfectious DiseasesEnzymeBiochemistryCovalent bondSortase ABacterial virulenceNIH 3T3 CellsStructure basedACS infectious diseases
researchProduct

Synthesis and biofilm formation reduction of pyrazole-4-carboxamide derivatives in some Staphylococcus aureus strains

2016

The ability of several N-phenyl-1H-pyrazole-4-carboxamide derivatives and other pyrazoles opportunely modified at the positions 3, 4 and 5, to reduce the formation of the biofilm in some Staphylococcus aureus strains (ATCC 29213, ATCC 25923 and ATCC 6538) were investigated. All the tested compounds were able, although to a different extent, to reduce the biofilm formation of the three bacterial strains considered. Among these, the 1-(2,5-dichlorophenyl)-5-methyl-N-phenyl-1H-pyrazole-4-carboxamide 14 resulted as the best inhibitor of biofilm formation showing an IC50 ranging from 2.3 to 32 μM, against all the three strains of S. aureus. Compound 14 also shows a good protective effect in vivo…

0301 basic medicineStaphylococcus aureusmedicine.drug_class030106 microbiologyCarboxamideMothsN-phenyl-1H-pyrazole-4-carboxamidePyrazoleSettore BIO/19 - Microbiologia Generalemedicine.disease_cause01 natural sciencesMicrobiologyStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundDrug DiscoveryInhibition of biofilm formationmedicineAnimalsIC50PharmacologyWaxVirulencebiology010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceAnti-virulenceOrganic ChemistryBiofilmS. aureuGeneral MedicineStaphylococcal Infectionsbiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticaAnti-Bacterial Agents0104 chemical sciencesGalleria mellonellaHydrazinesSettore AGR/11 - Entomologia Generale E ApplicatachemistryStaphylococcus aureusBiofilmsLarvavisual_artWax moth larva modelvisual_art.visual_art_mediumPyrazolesLead compoundEuropean Journal of Medicinal Chemistry
researchProduct

Prioritizing covariates in the planning of future studies in the meta-analytic framework

2016

Science can be seen as a sequential process where each new study augments evidence to the existing knowledge. To have the best prospects to make an impact in this process, a new study should be designed optimally taking into account the previous studies and other prior information. We propose a formal approach for the covariate prioritization, i.e., the decision about the covariates to be measured in a new study. The decision criteria can be based on conditional power, change of the p-value, change in lower confidence limit, Kullback-Leibler divergence, Bayes factors, Bayesian false discovery rate or difference between prior and posterior expectation. The criteria can be also used for decis…

0301 basic medicineStatistics and ProbabilityFalse discovery rateComputer scienceBayesian probabilityBayes factorGeneral MedicineMultiple-criteria decision analysis01 natural sciencesConfidence interval010104 statistics & probability03 medical and health sciences030104 developmental biologySample size determinationCovariateEconometrics0101 mathematicsStatistics Probability and UncertaintyDivergence (statistics)Biometrical Journal
researchProduct